On December 27, Aimei Vaccine announced that it held an investor open day event on December 22. Almost 40 investment institutions, including CITIC Securities, CITIC Construction Investment Securities, Guotai Junan Securities, and CMB International Securities, visited and toured Aimei's bacterial vaccine industrialization base and mRNA and viral vaccine industrialization production base in Ningbo. They engaged in on-site visits, discussions, and exchanges, gaining detailed insight into the upcoming innovative vaccine products slated for market launch and their production workshop construction, as well as understanding the layout and development plans of the company's product pipeline.

During the visit, investors were given tours of two completed vaccine factories, including the serum-free iteration rabies vaccine workshop, new process diploid cell rabies vaccine workshop, mRNA vaccine series workshop, as well as iteration pneumonia series vaccine workshop, tetravalent meningococcal vaccine workshop, Hib-DTP combined vaccine workshop, and modernized quality control laboratory. Samples for the third-phase clinical trials of the upcoming serum-free iteration rabies vaccine, 13-valent pneumococcal conjugate vaccine, and 23-valent pneumococcal polysaccharide vaccine were all produced in the mentioned workshops.

According to reports, the latest serum-free iteration rabies vaccine developed by Aimei is an upgraded product. Compared to current "serum-containing rabies vaccines" in the market, such as Vero cell and human diploid cell rabies vaccines, this vaccine has achieved a technological breakthrough by not adding any animal serum, resulting in improved safety and reduced adverse reactions. It is anticipated that this product will apply for market approval next year.

Meanwhile, on the front of pneumonia-related vaccines, utilizing the advantages of polysaccharide conjugate vaccine technology platform, the company has developed a series of polysaccharide conjugate vaccine products. It is expected that the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine will apply for registration and enter the market in 2024. Additionally, Aimei Vaccine has pioneered the development of the iterative upgraded products 20-valent pneumococcal conjugate vaccine and 24-valent pneumococcal conjugate vaccine. Currently, the 20-valent pneumococcal conjugate vaccine is in the pre-communication stage with the Center for Drug Evaluation (CDE).

Regarding the market's attention to the commercialization process of the 13-valent pneumococcal conjugate vaccine, Aimei Vaccine stated that the product production line has already completed production validation, and samples used for the third-phase clinical trials were all produced by this production line, eliminating the need for subsequent bridging trials and significantly expediting the entire product's market approval process.

Moreover, Aimei Vaccine mentioned that the company is highly focused on the application of vaccines in non-communicable disease fields and has initiated research and development work on tumor vaccines such as melanoma and lung cancer. Active exploration is also underway for Alzheimer's disease vaccines and diabetes vaccines.

When discussing internationalization strategies, Aimei stated that the company's future main focus for international markets will be in Southeast Asia, Africa, South America, the Middle East, and does not rule out entering the European and American markets in the future.